<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37371540</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>29</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2218-273X</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Jun</Month><Day>08</Day></PubDate></JournalIssue><Title>Biomolecules</Title><ISOAbbreviation>Biomolecules</ISOAbbreviation></Journal><ArticleTitle>Immune Phenotype as a Biomarker for Systemic Lupus Erythematosus.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">960</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/biom13060960</ELocationID><Abstract><AbstractText>The treatment of rheumatoid arthritis was revolutionized with the use of molecular-targeted drugs that target immunoregulatory molecules. The success of treatment with these drugs prompted the development of molecular-targeted drugs for systemic lupus erythematosus. However, systemic lupus erythematosus is a disease with high heterogeneous immune abnormalities, and diverse cells or molecules can be treatment targets. Thus, the identification of subpopulations based on immune abnormalities is essential for the development of effective treatment. One analytical method used to identify subpopulations is the immunophenotyping of peripheral blood samples of patients. This analysis evaluates the validity of target molecules for peripheral blood immune cell subsets, which are expected to be developed as biomarkers for precision medicine in which appropriate treatment targets are set for each subpopulation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nakayamada</LastName><ForeName>Shingo</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-2209-8454</Identifier><AffiliationInfo><Affiliation>The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahata-nishi-ku, Kitakyushu 807-8555, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanaka</LastName><ForeName>Yoshiya</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-0807-7139</Identifier><AffiliationInfo><Affiliation>The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahata-nishi-ku, Kitakyushu 807-8555, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Biomolecules</MedlineTA><NlmUniqueID>101596414</NlmUniqueID><ISSNLinking>2218-273X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001172" MajorTopicYN="Y">Arthritis, Rheumatoid</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">biomarkers</Keyword><Keyword MajorTopicYN="N">immunophenotyping</Keyword><Keyword MajorTopicYN="N">precision medicine</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword></KeywordList><CoiStatement>S.N. received consulting fees, speaking fees, and/or honoraria from Bristol-Myers, AstraZeneca, Pfizer, GlaxoSmithKline, Astellas, Asahi-Kasei, Sanofi, Abbvie, Eisai, Chugai, Gilead, and Boehringer Ingelheim. Y.T. received consulting fees, speaking fees, and/or honoraria from Abbvie, Daiichi-Sankyo, Chugai, Takeda, Mitsubishi-Tanabe, Bristol-Myers, Astellas, Eisai, Janssen, Pfizer, Asahi-Kasei, Eli Lilly, GlaxoSmithKline, UCB, Teijin, MSD, and Santen, as well as research grants from Mitsubishi-Tanabe, Takeda, Chugai, Astellas, Eisai, Taisho-Toyama, Kyowa-Kirin, Abbvie, and Bristol-Myers.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>5</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>29</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>28</Day><Hour>1</Hour><Minute>7</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37371540</ArticleId><ArticleId IdType="pmc">PMC10295858</ArticleId><ArticleId IdType="doi">10.3390/biom13060960</ArticleId><ArticleId IdType="pii">biom13060960</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tsokos G.C. Systemic lupus erythematosus. N. Engl. J. Med. 2011;365:2110&#x2013;2121. doi: 10.1056/NEJMra1100359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1100359</ArticleId><ArticleId IdType="pubmed">22129255</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka Y. State-of-the-art treatment of systemic lupus erythematosus. Int. J. Rheum. Dis. 2020;23:465&#x2013;471. doi: 10.1111/1756-185X.13817.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1756-185X.13817</ArticleId><ArticleId IdType="pmc">PMC7187183</ArticleId><ArticleId IdType="pubmed">32134201</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Vollenhoven R.F., Mosca M., Bertsias G., Isenberg D., Kuhn A., Lerstr&#xf8;m K., Aringer M., Bootsma H., Boumpas D., Bruce I.N., et al. Treat-to-target in systemic lupus erythematosus: Recommendations from an international task force. Ann. Rheum. Dis. 2014;73:958. doi: 10.1136/annrheumdis-2013-205139.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2013-205139</ArticleId><ArticleId IdType="pubmed">24739325</ArticleId></ArticleIdList></Reference><Reference><Citation>Gravallese E.M., Firestein G.S. Rheumatoid Arthritis&#x2014;Common Origins, Divergent Mechanisms. N. Engl. J. Med. 2023;388:529&#x2013;542. doi: 10.1056/NEJMra2103726.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra2103726</ArticleId><ArticleId IdType="pubmed">36780677</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy G., Isenberg D.A. New therapies for systemic lupus erythematosus&#x2014;Past imperfect, future tense. Nat. Rev. Rheumatol. 2019;15:403&#x2013;412. doi: 10.1038/s41584-019-0235-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-019-0235-5</ArticleId><ArticleId IdType="pubmed">31165780</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand E.F., Furie R., Tanaka Y., Bruce I.N., Askanase A.D., Richez C., Bae S.-C., Brohawn P.Z., Pineda L., Berglind A., et al. Trial of Anifrolumab in Active Systemic Lupus Erythematosus. N. Engl. J. Med. 2020;382:211&#x2013;221. doi: 10.1056/NEJMoa1912196.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1912196</ArticleId><ArticleId IdType="pubmed">31851795</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka Y., Tummala R. Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: An overview from clinical trials. Mod. Rheumatol. 2021;31:1&#x2013;12. doi: 10.1080/14397595.2020.1812201.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14397595.2020.1812201</ArticleId><ArticleId IdType="pubmed">32814461</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace D.J., Gudsoorkar V.S., Weisman M.H., Venuturupalli S.R. New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. Nat. Rev. Rheumatol. 2012;8:522&#x2013;533. doi: 10.1038/nrrheum.2012.106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2012.106</ArticleId><ArticleId IdType="pubmed">22801982</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakata K., Nakayamada S., Miyazaki Y., Kubo S., Ishii A., Nakano K., Tanaka Y. Up-Regulation of TLR7-Mediated IFN-&#x3b1; Production by Plasmacytoid Dendritic Cells in Patients with Systemic Lupus Erythematosus. Front. Immunol. 2018;9:1957. doi: 10.3389/fimmu.2018.01957.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.01957</ArticleId><ArticleId IdType="pmc">PMC6121190</ArticleId><ArticleId IdType="pubmed">30210502</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco P., Palucka A.K., Gill M., Pascual V., Banchereau J. Induction of dendric cell differentiation by IFN-alpha in systemic lu-pus erythematosus. Science. 2001;294:1540&#x2013;1543. doi: 10.1126/science.1064890.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1064890</ArticleId><ArticleId IdType="pubmed">11711679</ArticleId></ArticleIdList></Reference><Reference><Citation>Sumikawa M.H., Iwata S., Zhang M., Miyata H., Ueno M., Todoroki Y., Nagayasu A., Kanda R., Sonomoto K., Torimoto K., et al. An enhanced mitochondrial function through glutamine metabo-lism in plasmablast differentiation in systemic lupus erythematosus. Rheumatology. 2022;61:3049&#x2013;3059. doi: 10.1093/rheumatology/keab824.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keab824</ArticleId><ArticleId IdType="pubmed">34730825</ArticleId></ArticleIdList></Reference><Reference><Citation>Ronnblom I., Elkon K.B. Cytokines as therapeutic targets in SLE. Nat. Rev. Rheumatol. 2010;6:339. doi: 10.1038/nrrheum.2010.64.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2010.64</ArticleId><ArticleId IdType="pubmed">20440285</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsubata T. B-cell tolerance and autoimmunity. F1000Research. 2017;6:391. doi: 10.12688/f1000research.10583.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.10583.1</ArticleId><ArticleId IdType="pmc">PMC5373417</ArticleId><ArticleId IdType="pubmed">28408984</ArticleId></ArticleIdList></Reference><Reference><Citation>Sj&#xf6;strand M., Johansson A., Aqrawi L., Olsson T., Wahren-Herlenius M., Espinosa A. The Expression of BAFF Is Controlled by IRF Transcription Factors. J. Immunol. 2016;196:91&#x2013;96. doi: 10.4049/jimmunol.1501061.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1501061</ArticleId><ArticleId IdType="pmc">PMC4683359</ArticleId><ArticleId IdType="pubmed">26590315</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson N., Gatenby P.A., Wilson A., Malik S., Fulcher D.A., Tangye S.G., Manku H., Vyse T.J., Roncador G., Huttley G.A., et al. Expansion of circulating T cells resembling follicular helper T cells is a fixed phenotype that identifies a subset of severe systemic lupus erythematosus. Arthritis Rheum. 2010;62:234&#x2013;244. doi: 10.1002/art.25032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.25032</ArticleId><ArticleId IdType="pubmed">20039395</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong C.K., Wong P.T., Tam L.S., Li E.K., Chen D.P., Lam C.W. Elevated production of B cell chemokine CXCL13 is correlated with systemic lupus erythematosus disease activity. J. Clin. Immunol. 2010;30:45&#x2013;52. doi: 10.1007/s10875-009-9325-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-009-9325-5</ArticleId><ArticleId IdType="pubmed">19774453</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi J.Y., Ho J.H., Pasoto S.G., Bunin V., Kim S.T., Carrasco S., Borba E.F., Gon&#xe7;alves C.R., Costa P.R., Kallas E.G., et al. Circulating follicular helper-like T cells in systemic lupus erythematosus: Association with disease activity. Arthritis Rheumatol. 2015;67:988&#x2013;999. doi: 10.1002/art.39020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39020</ArticleId><ArticleId IdType="pmc">PMC4450082</ArticleId><ArticleId IdType="pubmed">25581113</ArticleId></ArticleIdList></Reference><Reference><Citation>Arazi A., Rao D.A., Berthier C.C., Davidson A., Liu Y., Hoover P.J., Chicoine A., Eisenhaure T.M., Jonsson A.H., Li S., et al. The immune cell landscape in kidneys of patients with lupus nephri-tis. Nat. Immunol. 2019;20:902&#x2013;914. doi: 10.1038/s41590-019-0398-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-019-0398-x</ArticleId><ArticleId IdType="pmc">PMC6726437</ArticleId><ArticleId IdType="pubmed">31209404</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakayamada S., Tanaka Y. Clinical relevance of T follicular helper cells in systemic lupus erythematosus. Expert Rev. Clin. Immunol. 2021;17:1143&#x2013;1150. doi: 10.1080/1744666X.2021.1976146.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1744666X.2021.1976146</ArticleId><ArticleId IdType="pubmed">34469695</ArticleId></ArticleIdList></Reference><Reference><Citation>Crotty S.T. Follicular Helper Cell Differentiation, Function, and Roles in Disease. Immunity. 2014;41:529&#x2013;542. doi: 10.1016/j.immuni.2014.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2014.10.004</ArticleId><ArticleId IdType="pmc">PMC4223692</ArticleId><ArticleId IdType="pubmed">25367570</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao D.A., Gurish M.F., Goodman V.P.B.S.M., Pernis V.P.B.S.M.G.A.B., Marshall J.L., Ivashkiv L.T.D.A.B.P.L.B., Karlson E.W., Nigrovic L.A.H.P.A., Filer A., Buckley J.L.M.A.F.C.D., et al. Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis. Nature. 2017;542:110&#x2013;114. doi: 10.1038/nature20810.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature20810</ArticleId><ArticleId IdType="pmc">PMC5349321</ArticleId><ArticleId IdType="pubmed">28150777</ArticleId></ArticleIdList></Reference><Reference><Citation>Bocharnikov A.V., Keegan J., Wacleche V.S., Cao Y., Fonseka C.Y., Wang G., Muise E., Zhang K.X., Arazi A., Keras G., et al. PD-1hiCXCR5&#x2013; T peripheral helper cells promote B cell responses in lupus via MAF and IL-21. J. Clin. Investig. 2019;4:e130062. doi: 10.1172/jci.insight.130062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.130062</ArticleId><ArticleId IdType="pmc">PMC6824311</ArticleId><ArticleId IdType="pubmed">31536480</ArticleId></ArticleIdList></Reference><Reference><Citation>Crisp&#xed;n J.C., Kyttaris V.C., Terhorst C., Tsokos G.C. T cells as therapeutic targets in SLE. Nat. Rev. Rheumatol. 2010;6:317&#x2013;325. doi: 10.1038/nrrheum.2010.60.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2010.60</ArticleId><ArticleId IdType="pmc">PMC2924434</ArticleId><ArticleId IdType="pubmed">20458333</ArticleId></ArticleIdList></Reference><Reference><Citation>Linterman M.A., Pierson W., Lee S.K., Kallies A., Kawamoto S., Rayner T.F., Srivastava M., Divekar D.P., Beaton L., Hogan J.J., et al. Foxp3+ follicular regulatory T cells control the germinal center response. Nat. Med. 2011;17:975&#x2013;982. doi: 10.1038/nm.2425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.2425</ArticleId><ArticleId IdType="pmc">PMC3182542</ArticleId><ArticleId IdType="pubmed">21785433</ArticleId></ArticleIdList></Reference><Reference><Citation>Wollenberg I., Agua-Doce A., Hern&#xe1;ndez A., Almeida C., Oliveira V.G., Faro J., Graca L. Regulation of the Germinal Center Reaction by Foxp3+ Follicular Regulatory T Cells. J. Immunol. 2011;187:4553&#x2013;4560. doi: 10.4049/jimmunol.1101328.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1101328</ArticleId><ArticleId IdType="pubmed">21984700</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung Y., Tanaka S., Chu F., Nurieva R.I., Martinez G.J., Rawal S., Wang Y.H., Lim H., Reynolds J.M., Zhou X.H., et al. Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress ger-minal center reactions. Nat. Med. 2011;17:983. doi: 10.1038/nm.2426.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.2426</ArticleId><ArticleId IdType="pmc">PMC3151340</ArticleId><ArticleId IdType="pubmed">21785430</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng J., Wei Y., Fonseca V.R., Graca L., Yu D. T follicular helper cells and T follicular regulatory cells in rheumatic diseases. Nat. Rev. Rheumatol. 2019;15:475&#x2013;490. doi: 10.1038/s41584-019-0254-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-019-0254-2</ArticleId><ArticleId IdType="pubmed">31289377</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu B., Wang S., Zhou M., Huang Y., Fu R., Guo C., Chen J., Zhao J., Gaskin F., Fu S.M., et al. The ratio of circulating follicular T helper cell to follicular T regulatory cell is correlated with disease activity in systemic lupus erythematosus. Clin. Immunol. 2017;183:46&#x2013;53. doi: 10.1016/j.clim.2017.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2017.07.004</ArticleId><ArticleId IdType="pmc">PMC5673570</ArticleId><ArticleId IdType="pubmed">28709914</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C., Wang D., Song Y., Lu S., Zhao J., Wang H. Increased circulating CD4+CXCR5+FoxP3+ follicular regulatory T cells correlated with severity of systemic lupus erythematosus patients. Int. Immunopharmacol. 2018;56:261&#x2013;268. doi: 10.1016/j.intimp.2018.01.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2018.01.038</ArticleId><ArticleId IdType="pubmed">29414660</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurosaki T., Shinohara H., Baba Y. B Cell Signaling and Fate Decision. Annu. Rev. Immunol. 2010;28:21&#x2013;55. doi: 10.1146/annurev.immunol.021908.132541.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.immunol.021908.132541</ArticleId><ArticleId IdType="pubmed">19827951</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinuesa C.G., Linterman M.A., Yu D., MacLennan I.C. Follicular Helper T cells. Annu. Rev. Immunol. 2016;24:335&#x2013;368. doi: 10.1146/annurev-immunol-041015-055605.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-immunol-041015-055605</ArticleId><ArticleId IdType="pubmed">26907215</ArticleId></ArticleIdList></Reference><Reference><Citation>Bossen C., Schneider P. BAFF, APRIL and their receptors: Structure, function and signaling. Semin. Immunol. 2006;18:263&#x2013;275. doi: 10.1016/j.smim.2006.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.smim.2006.04.006</ArticleId><ArticleId IdType="pubmed">16914324</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancro M.P., D&#x2019;cruz D.P., Khamashta M.A. The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J. Clin. Investig. 2009;119:1066&#x2013;1073. doi: 10.1172/JCI38010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI38010</ArticleId><ArticleId IdType="pmc">PMC2673851</ArticleId><ArticleId IdType="pubmed">19411764</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakayamada S., Tanaka Y. BAFF- and APRIL-targeted therapy in systemic autoimmune diseases. Inflamm. Regen. 2016;36:6. doi: 10.1186/s41232-016-0015-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41232-016-0015-4</ArticleId><ArticleId IdType="pmc">PMC5725651</ArticleId><ArticleId IdType="pubmed">29259679</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson B.A., Kahler D.J., Baban B., Chandler P.R., Kang B., Shimoda M., Koni P.A., Pihkala J., Vilagos B., Busslinger M., et al. B-lymphoid cells with attributes of dendritic cells regulate T cells via indoleamine 2,3-dioxygenase. Proc. Natl. Acad. Sci. USA. 2010;107:10644&#x2013;10648. doi: 10.1073/pnas.0914347107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0914347107</ArticleId><ArticleId IdType="pmc">PMC2890795</ArticleId><ArticleId IdType="pubmed">20498068</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubtsov A.V., Rubtsova K., Fischer A., Meehan R.T., Gillis J.Z., Kappler J.W., Marrack P. Toll-like receptor 7 (TLR7)&#x2013;driven accumulation of a novel CD11c+ B-cell population is important for the development of autoimmunity. Blood. 2011;118:1305&#x2013;1315. doi: 10.1182/blood-2011-01-331462.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2011-01-331462</ArticleId><ArticleId IdType="pmc">PMC3152497</ArticleId><ArticleId IdType="pubmed">21543762</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S., Wang J., Kumar V., Karnell J.L., Naiman B., Gross P.S., Rahman S., Zerrouki K., Hanna R., Morehouse C., et al. IL-21 drives expansion and plasma cell differentiation of autoreactive CD11chiT-bet+ B cells in SLE. Nat. Commun. 2018;9:1758. doi: 10.1038/s41467-018-03750-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-03750-7</ArticleId><ArticleId IdType="pmc">PMC5931508</ArticleId><ArticleId IdType="pubmed">29717110</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenks S.A., Cashman K.S., Zumaquero E., Marigorta U.M., Patel A.V., Wang X., Tomar D., Woodruff M.C., Simon Z., Bugrovsky R., et al. Distinct Effector B Cells Induced by Unregulated Toll-like Receptor 7 Contribute to Pathogenic Responses in Systemic Lupus Erythematosus. Immunity. 2018;49:725&#x2013;739. doi: 10.1016/j.immuni.2018.08.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2018.08.015</ArticleId><ArticleId IdType="pmc">PMC6217820</ArticleId><ArticleId IdType="pubmed">30314758</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez O.D., Mitchell D., Campos R., Gao G.J., Li L., Nolan G.P. Multiparameter analysis of intracellular phosphoepitopes in immunophenotyped cell pop-ulations by flow cytometry. Curr. Protoc. Cytom. 2005;32:6.20.1&#x2013;6.20.22.</Citation><ArticleIdList><ArticleId IdType="pubmed">18770823</ArticleId></ArticleIdList></Reference><Reference><Citation>Parish C.R., Glidden M.H., Quah B.J., Warren H.S. Use of the intracellular fluorescent dye CFSE to monitor lymphocyte migration and pro-liferation. Curr. Protoc. Immunol. 2009;84:4.9.1&#x2013;4.9.13.</Citation><ArticleIdList><ArticleId IdType="pubmed">19235770</ArticleId></ArticleIdList></Reference><Reference><Citation>Maecker H.T., McCoy J.P., Nussenblatt R. Standardizing immunophenotyping for the Human Immunology Project. Nat. Rev. Immunol. 2012;12:191&#x2013;200. doi: 10.1038/nri3158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3158</ArticleId><ArticleId IdType="pmc">PMC3409649</ArticleId><ArticleId IdType="pubmed">22343568</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakayamada S., Kubo S., Yoshikawa M., Miyazaki Y., Yunoue N., Iwata S., Miyagawa I., Hirata S., Nakano K., Saito K., et al. Differential effects of biological DMARDs on peripheral immune cell phenotypes in patients with rheumatoid arthritis. Rheumatology. 2018;57:164&#x2013;174. doi: 10.1093/rheumatology/kex012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kex012</ArticleId><ArticleId IdType="pubmed">28371836</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka Y. Psoriatic arthritis in Japan: Difference in clinical features and approach to precision medicine. Clin. Exp. Rheumatol. 2016;34:49&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">27586804</ArticleId></ArticleIdList></Reference><Reference><Citation>Kubo S., Nakayamada S., Yoshikawa M., Miyazaki Y., Sakata K., Nakano K., Hanami K., Iwata S., Miyagawa I., Saito K., et al. Peripheral Immunophenotyping Identifies Three Subgroups Based on T Cell Heterogeneity in Lupus Patients. Arthritis Rheumatol. 2017;69:2029&#x2013;2037. doi: 10.1002/art.40180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40180</ArticleId><ArticleId IdType="pubmed">28605137</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma X., Nakayamada S., Kubo S., Sakata K., Yamagata K., Miyazaki Y., Yoshikawa M., Kitanaga Y., Zhang M., Tanaka Y. Expansion of T follicular helper-T helper 1 like cells through epige-netic regulation by signal transducer and activator of transcription factors. Ann. Rheum. Dis. 2018;77:1354. doi: 10.1136/annrheumdis-2017-212652.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2017-212652</ArticleId><ArticleId IdType="pubmed">29853448</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma X., Nakayamada S., Wang J. Multi-source pathways of T follicular helper cell differentiation. Front Immunol. 2021;12:621105. doi: 10.3389/fimmu.2021.621105.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.621105</ArticleId><ArticleId IdType="pmc">PMC7947315</ArticleId><ArticleId IdType="pubmed">33717120</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao H., Nakayamada S., Yamagata K., Ohkubo N., Iwata S., Inoue Y., Zhang M., Zhang T., Satoh Y.K., Shan Y., et al. Conversion of T Follicular Helper Cells to T Follicular Regulatory Cells by Interleukin-2 Through Transcriptional Regulation in Systemic Lupus Erythematosus. Arthritis Rheumatol. 2021;73:132&#x2013;142. doi: 10.1002/art.41457.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41457</ArticleId><ArticleId IdType="pubmed">32720470</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao H., Nakayamada S., Tanaka Y. Differentiation, functions, and roles of T follicular regulatory cells in autoimmune diseases. Inflamm. Regen. 2021;41:14. doi: 10.1186/s41232-021-00164-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41232-021-00164-9</ArticleId><ArticleId IdType="pmc">PMC8088831</ArticleId><ArticleId IdType="pubmed">33934711</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao H., Nakayamada S., Ohkubo N., Yamagata K., Zhang M., Shan Y., Iwata S., Zhang T., Tanaka Y. Involvement of lncRNA IL21-AS1 in interleukin-2 and T follic-ular regulatory cell activation in systemic lupus erythematosus. Arthritis Res. Ther. 2021;23:302. doi: 10.1186/s13075-021-02682-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-021-02682-w</ArticleId><ArticleId IdType="pmc">PMC8665514</ArticleId><ArticleId IdType="pubmed">34895341</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanemura S., Seki N., Tsujimoto H., Saito S., Kikuchi J., Sugahara K., Yoshimoto K., Suzuki K., Kaneko Y., Chiba K., et al. Role of interferons (IFNs) in the differentiation of T peripheral helper (Tph) cells. Int. Immunol. 2022;34:533&#x2013;544. doi: 10.1093/intimm/dxac032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/intimm/dxac032</ArticleId><ArticleId IdType="pubmed">35780437</ArticleId></ArticleIdList></Reference><Reference><Citation>Shan Y., Nakayamada S., Nawata A., Yamagata K., Sonomoto K., Tanaka H., Satoh-Kanda Y., Nguyen M.-P., Todoroki Y., Nagayasu A., et al. TGF-&#x3b2;3 in differentiation and function of Tph-like cells and its relevance to disease activity in patients with systemic lupus erythematosus. Rheumatology. 2022 doi: 10.1093/rheumatology/keac646. ahead of print .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keac646</ArticleId><ArticleId IdType="pubmed">36370078</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins F.S., Varmus H. A New Initiative on Precision Medicine. N. Engl. J. Med. 2015;372:793&#x2013;795. doi: 10.1056/NEJMp1500523.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp1500523</ArticleId><ArticleId IdType="pmc">PMC5101938</ArticleId><ArticleId IdType="pubmed">25635347</ArticleId></ArticleIdList></Reference><Reference><Citation>Jameson J.L., Longo D.L. Precision medicine&#x2014;Personalized, problematic, and promising. N. Engl. J. Med. 2015;372:2229&#x2013;2234. doi: 10.1056/NEJMsb1503104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMsb1503104</ArticleId><ArticleId IdType="pubmed">26014593</ArticleId></ArticleIdList></Reference><Reference><Citation>Banchereau R., Hong S., Cantarel B., Baldwin N., Baisch J., Edens M., Cepika A.M., Acs P., Turner J., Anguiano E., et al. Personalized Immunomonitoring Uncovers Molecular Net-works that Stratify Lupus Patients. Cell. 2016;165:551&#x2013;565. doi: 10.1016/j.cell.2016.03.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.03.008</ArticleId><ArticleId IdType="pmc">PMC5426482</ArticleId><ArticleId IdType="pubmed">27040498</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagberg N., Joelsson M., Leonard D., Reid S., Eloranta M.L., Mo J., Nilsson M.K., Syv&#xe4;nen A.C., Bryceson Y.T., R&#xf6;nnblom L. The STAT4 SLE risk allele rs7574865[T] is associated with in-creased IL-12-induced IFN-&#x3b3; production in T cells from patients with SLE. Ann. Rheum. Dis. 2018;77:1070. doi: 10.1136/annrheumdis-2017-212794.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2017-212794</ArticleId><ArticleId IdType="pmc">PMC6029643</ArticleId><ArticleId IdType="pubmed">29475858</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel Z.H., Lu X., Miller D., Forney C.R., Lee J., Lynch A., Schroeder C., Parks L., Magnusen A.F., Chen X., et al. A plausibly causal functional lupus-associated risk variant in the STAT1&#x2013;STAT4 locus. Hum. Mol. Genet. 2018;27:2392&#x2013;2404. doi: 10.1093/hmg/ddy140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddy140</ArticleId><ArticleId IdType="pmc">PMC6005081</ArticleId><ArticleId IdType="pubmed">29912393</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanata C.M., Paranjpe I., Nititham J., Taylor K.E., Gianfrancesco M., Paranjpe M., Andrews S., Chung S.A., Rhead B., Barcellos L.F., et al. A phenotypic and genomics approach in a multi-ethnic cohort to subtype systemic lupus erythematosus. Nat. Commun. 2019;10:3902. doi: 10.1038/s41467-019-11845-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-11845-y</ArticleId><ArticleId IdType="pmc">PMC6715644</ArticleId><ArticleId IdType="pubmed">31467281</ArticleId></ArticleIdList></Reference><Reference><Citation>Oke V., Gunnarsson I., Dorschner J., Eketj&#xe4;ll S., Zickert A., Niewold T.B., Svenungsson E. High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus. Arthritis Res. Ther. 2019;21:107. doi: 10.1186/s13075-019-1878-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-019-1878-y</ArticleId><ArticleId IdType="pmc">PMC6489203</ArticleId><ArticleId IdType="pubmed">31036046</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradley S.J., Su&#xe1;rez-Fueyo A., Moss D.R., Kyttaris V.C., Tsokos G.C. T Cell Transcriptomes Describe Patient Subtypes in Systemic Lupus Erythematosus. PLoS ONE. 2015;10:e0141171. doi: 10.1371/journal.pone.0141171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0141171</ArticleId><ArticleId IdType="pmc">PMC4636226</ArticleId><ArticleId IdType="pubmed">26544975</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakano M., Ota M., Takeshima Y., Iwasaki Y., Hatano H., Nagafuchi Y., Itamiya T., Maeda J., Yoshida R., Yamada S., et al. Distinct transcriptome architectures underlying lupus establishment and exacerbation. Cell. 2022;185:3375&#x2013;3389.e21. doi: 10.1016/j.cell.2022.07.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.07.021</ArticleId><ArticleId IdType="pubmed">35998627</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>